《新股消息》智欣集团(02187.HK)公开发售超购24倍 一手中签率10%
内地混凝土建材制造商及供应商智欣集团(02187.HK)公布招股结果,发售价定於1.5元,公开发售录超购24.24倍,经重新分配後,公开发售股数增至20%。每手8,000股,中签率为10%。该股将於明日(3月26日)上市,新华汇富为独家保荐人。
公司预计,发售所得款项净额约2.41亿元,当中82.7%将用於扩大预制混凝土构件厂房的预制混凝土构件产能;3.6%用於引入企业资源规划系统以提升资讯科技系统;3.2%用於改善环境保护系统。另外,部分款项用於购置搅拌车和混凝土泵车、以及用作一般营运资金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.